52 Amendments of Françoise GROSSETÊTE related to 2011/0401(COD)
Amendment 64 #
Proposal for a regulation
Recital 30 a (new)
Recital 30 a (new)
(30a) The participation of research teams in different projects should be contemplated as the reinforcement of quality and the possibility of an international co-operation.
Amendment 73 #
Proposal for a regulation
Article 4 – paragraph 1
Article 4 – paragraph 1
Horizon 2020 shall play a central role in the delivery of the Europe 2020 strategy for smart, sustainable and inclusive growth by providing a common strategic framework for the Union's research and innovation funding, thus acting as a vehicle for leveraging private investment, transferring research results to all the levels of education, creating new job opportunities and ensuring Europe's long- term sustainable growth and competitiveness.
Amendment 111 #
Proposal for a regulation
Article 14 – paragraph 1
Article 14 – paragraph 1
Horizon 2020 shall be implemented in a manner ensuring that the priorities and actions supported are relevant to changing needs and take account of the evolving nature of science, technology, innovation, markets and society, where innovation includes business, organisational and social aspects and transfer of science results to all the levels of education and training.
Amendment 142 #
Proposal for a regulation
Article 19 – paragraph 3 – point e a (new)
Article 19 – paragraph 3 – point e a (new)
(ea) Helping the creation and strengthening of association networks of researchers, patients and stakeholders in order to improve the relations and exchanges among them, concerned sectors, institutions and civil society.
Amendment 178 #
Proposal for a regulation
Annex I – part II – point 1 – paragraph 8 'An integrated approach to Key Enabling Technologies'
Annex I – part II – point 1 – paragraph 8 'An integrated approach to Key Enabling Technologies'
A major component of ‘Leadership in Enabling and Industrial Technologies’ are Key Enabling Technologies (KETs), defined as micro- and nanoelectronics, photonics, nanotechnology, biotechnology, advanced materials and advanced manufacturing systems22 . These multi- disciplinary, knowledge and capital- intensive technologies cut across many diverse sectors providing the basis for significant competitive advantage for European industry. An integrated approach, promoting the combination, convergence and cross-fertilisation effect of KETs in different innovation cycles and value chains can deliver promising research results and open the way to new industrial technologies, products, services and novel applications (e.g. in space, transport, environment, health, agriculture etc.). The numerous interactions of KETs and enabling technologies will therefore be exploited in a flexible manner, as an important source of innovation. This will complement support for research and innovation in KETs that may be provided by national or regional authorities under the Cohesion Policy Funds within the framework of smart specialisation strategies.
Amendment 180 #
Proposal for a regulation
Annex I – part II – point 1.1.3 – point e a (new)
Annex I – part II – point 1.1.3 – point e a (new)
(e a) advanced robots and technology applied to health and disabilities
Amendment 226 #
Proposal for a regulation
Annex I – part III – point 1.1 – paragraph 1
Annex I – part III – point 1.1 – paragraph 1
Lifelong health and wellbeing for all, high- quality and economically sustainable health and care systems, solutions to deal with the economy of an ageing population and opportunities for new jobs and growth are the aims of support to research and innovation in response to this challenge and will make a major contribution to Europe 2020.
Amendment 229 #
Proposal for a regulation
Annex I – part III – point 1.1 – paragraph 1 b (new)
Annex I – part III – point 1.1 – paragraph 1 b (new)
Research shall allow to improve advanced therapies and cellular therapies and would be focused on the treatment of chronic and degenerative diseases.
Amendment 249 #
Proposal for a regulation
Annex I – part III – point 1.1 – paragraph 4
Annex I – part III – point 1.1 – paragraph 4
In the Union, CVD annually accounts for more than 2 million deaths and costs the economy more than EUR 192 billion while cancer accounts for a quarter of all deaths and is the number one cause of death in people aged 45-64. Over 27 million people in the Union suffer from diabetes and the total cost of brain disorders (including, but not limited to those affecting mental health) has been estimated at EUR 800 billion. Environmental, life-style and socio-economic factors are relevant in several of these conditions with up to one third of the global disease burden estimated to be related to these. However, for other conditions – in particular neurodegenerative diseases – effective prevention strategies will first require a considerable boost in research into their causes and the development of better early diagnosis and treatment options.
Amendment 263 #
Proposal for a regulation
Recital 16
Recital 16
(16) In accordance with Article 182(1) TFEUof the Treaty on the Functioning of the European Union, the framework programme fixes the maximum overall amount and the detailed rules for Union financial participation in the framework programme and the respective shares in each of the activities provided for in Article 180 of the Treaty.
Amendment 265 #
Proposal for a regulation
Annex I – part III – point 1.2 – paragraph 2
Annex I – part III – point 1.2 – paragraph 2
The response depends on excellence in research to improve our fundamental understanding of health, disease, disability, development and ageing (including of life expectancy), and on the seamless and widespread translation of the resulting and existing knowledge into innovative, scalable and, effective and accessible products, strategies, interventions and services. Furthermore, the pertinence of these challenges across Europe and in many cases, globally, demands a response characterised by long term and coordinated support for co- operation between excellent, multidisciplinary and multi-sector teams.
Amendment 280 #
Proposal for a regulation
Annex I – part III – point 1.3 – paragraph 2a (new)
Annex I – part III – point 1.3 – paragraph 2a (new)
Personalised medicine must be developed, in order to generate new preventive and therapeutic strategies which can adjusted to patient requirements, so as to increase the prevention and early detection of diseases. The factors which influence therapeutic decision-making must be identified, further elucidated and developed through research.
Amendment 322 #
Proposal for a regulation
Recital 25
Recital 25
(25) The European Commission does not explicitly solicit the use of human embryonic stem cellsis concerned about matters of fairness in the use of human stem cells, whether adult, embryonic or from the umbilical cord. The use of human stem cells, be they adult or embryonic, if any, depends on the judgement of the scientists in view of the therapeutic objectives they want to achieve and is subject to stringent Ethics Review. No pProjects involving the use of human embryonic stem cells shouldmay be funded that does not obtain the necessary approvals fromprovided that they have been duly approved by the Member States concerned. No activity should be funded that is forbidden in all Member States. No activity should be funded in a Member State where such activity is forbidden. However, medical research on all types of stem cell shall be funded in Member States where such activity is authorised.
Amendment 331 #
Proposal for a regulation
Recital 25 a (new)
Recital 25 a (new)
(25a) The Commission should take better account in the framework programme of research on cells extracted from umbilical cord blood (capacity for differentiation, for proliferation and for autologous or allogeneic use, absence of immunological reaction in the patient receiving the cells), which have already been successfully used to treat certain conditions.
Amendment 333 #
Proposal for a regulation
Recital 25 b (new)
Recital 25 b (new)
(25b) The recent discovery of induced pluripotent stem cells (iPSCs) has opened up a new avenue for research, over and beyond the opportunities for research on adult and embryonic stem cells that have existed for several years, and has thus offered new hope to patients awaiting treatment. The Union should therefore take action, bearing in mind the following: - the scientific community’s interest in all types of research; - the need to strike a balance between the various ways of researching stem cells, without favouring any one over the others; - the importance of unprejudiced consideration of the ethical problems raised by each category of stem cells.
Amendment 350 #
Proposal for a regulation
Recital 27
Recital 27
(27) SMEs constitute a significantn essential source of innovation and, growth and jobs in Europe. Therefore a strong participation of SMEs, as defined in Commission Recommendation 2003/361/EC of 6 May 2003, is needed in Horizon 2020. This should support the aims of the Small Business Act.
Amendment 372 #
Proposal for a regulation
Recital 30 a (new)
Recital 30 a (new)
(30a) It should be contemplated to encourage the participation of research teams in different projects in order to reinforce the R&I quality and to increase the possibility of international co- operation.
Amendment 375 #
Proposal for a regulation
Annex I – part III – point 6.3.1 – paragraph 2 – point c
Annex I – part III – point 6.3.1 – paragraph 2 – point c
(c) ensure societal engagement in research and innovation; increase societal appreciation of science
Amendment 383 #
Proposal for a regulation
Article 4
Article 4
Horizon 2020 shall play a central role in the delivery of the Europe 2020 strategy for smart, sustainable and inclusive growth by providing a common strategic framework for the Union's research and innovation funding, thus acting as a vehicle for leveraging private investment, transferring research results to all the levels of education, creating new job opportunities and ensuring Europe's long- term sustainable growth and competitiveness.
Amendment 504 #
Proposal for a regulation
Article 14 – paragraph 1
Article 14 – paragraph 1
Horizon 2020 shall be implemented in a manner ensuring that the priorities and actions supported are relevant to changing needs and take account of the evolving nature of science, technology, innovation, markets and society, where innovation includes business, organisational and social aspects, as well as transfer of science results to all the levels of education and training.
Amendment 576 #
Proposal for a regulation
Article 16 – paragraph 4
Article 16 – paragraph 4
4. Research on human stem cells, bothwhether adult and, embryonic or from the umbilical cord, may be financed, depending both on the contents of the scientific proposal and the legal framework of the Member States involved. Research on embryonic stem cells may only be carried out using supernumerary embryos conceived via in vitro fertilisation and not needed for the purposes of reproduction. No funding shall be granted for research activities that are prohibited in all the Member States. No activity shall be funded in a Member State where such activity is forbidden. However, medical research on all types of stem cell shall be funded in Member States where such activity is authorised.
Amendment 659 #
Proposal for a regulation
Article 19 – paragraph 3 – point e a (new)
Article 19 – paragraph 3 – point e a (new)
(e a) the ability to assist the creation and strengthening of networks of researchers, patients and stakeholders in order to improve the relations and exchanges among them, concerned sectors, institutions and civil society;
Amendment 688 #
Proposal for a regulation
Article 21 – paragraph 2 – subparagraph 1
Article 21 – paragraph 2 – subparagraph 1
Targeted actions with the objective of promoting cooperation with specific third countries or groups of third countries shall be implemented on the basis of common interest and mutual benefit, taking into account their scientific and technological capabilities and market opportunit. These actions shall include, in particular, research capacity building in developing countries and cooperation projects focusing on these countries’ specific needs in areas such as health – including research on neglected diseases – as well as agriculture, fisheries, and the expected impactnvironment, and implemented in financial conditions adapted to their capacities.
Amendment 693 #
Proposal for a regulation
Article 21 – paragraph 2 – subparagraph 3
Article 21 – paragraph 2 – subparagraph 3
Cooperation priorities shall take into account developments in Union policy and opportunities for cooperation with third countries, as well as possible deficiencies in third country intellectual property systems.
Amendment 885 #
Proposal for a regulation
Annex 1 – Part 1 – point 2 – point 2.1 – paragraph 1
Annex 1 – Part 1 – point 2 – point 2.1 – paragraph 1
The specific objective is to foster radically new technologies by exploring novel and high-risk ideas building on scientific foundations, such as a better understanding of human pathologies and toxicity mechanisms, and the implementation in Union health research and in risk assessment strategies of tools and cellular, genome and IT technologies with human relevance. By providing flexible support to goal-oriented and interdisciplinary collaborative research on various scales and by adopting innovative research practices, the aim is to identify and seize opportunities of long-term benefit for citizens, the economy and society.
Amendment 888 #
Proposal for a regulation
Annex 1 – Part 1 – point 2 – point 2.2 – paragraph 1
Annex 1 – Part 1 – point 2 – point 2.2 – paragraph 1
Radical breakthroughs with a transformative impact increasingly rely on intense collaboration across disciplines in science and technology (for instance, information and communication, biology, bioengineering and robotics, chemistry, earth system sciences, material sciences, neuro- and cognitive sciences, social sciences or economics) and with the arts and humanities. This requires not only excellence in science and technology but also new attitudes and novel interactions between a broad range of players in research.
Amendment 1009 #
Proposal for a regulation
Annex 1 – Part 2 – point 1 – paragraph 12
Annex 1 – Part 2 – point 1 – paragraph 12
A major component of ‘'Leadership in Enabling and Industrial Technologies’' are Key Enabling Technologies (KETs), defined as micro- and nanoelectronics, photonics, nanotechnology, biotechnology, advanced materials and advanced manufacturing systems. These multi- disciplinary, knowledge and capital- intensive technologies cut across many diverse sectors providing the basis for significant competitive advantage for European industry. An integrated approach, promoting the combination, convergence and cross-fertilisation effect of KETs in different innovation cycles and value chains can deliver promising research results and open the way to new industrial technologies, products, services and novel applications (e.g. in space, transport, environment, health, agriculture etc.). The numerous interactions of KETs and enabling technologies will therefore be exploited in a flexible manner, as an important source of innovation. This will complement support for research and innovation in KETs that may be provided by national or regional authorities under the Cohesion Policy Funds within the framework of smart specialisation strategies.
Amendment 1039 #
Proposal for a regulation
Annex 1 – Part 2 – point 1 – point 1.1 – point 1.1.3 – point e a (new)
Annex 1 – Part 2 – point 1 – point 1.1 – point 1.1.3 – point e a (new)
(e a) advanced robots and technology applied to health and disabilities
Amendment 1050 #
Proposal for a regulation
Annex 1 – Part 2 – point 1 – point 1.2 – point 1.2.1 – paragraph 1
Annex 1 – Part 2 – point 1 – point 1.2 – point 1.2.1 – paragraph 1
The specific objective of nanotechnologies research and innovation is to secuprepare Union leadership in this high growth global market, by stimulating investment and patents in nanotechnologies and their uptake in high added-value, competitive products and services across a range of applications and sectors.
Amendment 1114 #
Proposal for a regulation
Annex 1 – Part 2 – point 1 – point 1.4 – point 1.4.1 – paragraph 1
Annex 1 – Part 2 – point 1 – point 1.4 – point 1.4.1 – paragraph 1
The specific objective of biotechnology research and innovation is to develop competitive, sustainable and innovative industrial products and processes and contribute as an innovation driver in a number of European sectors like agriculture, food, the chemical sector, energy and health.
Amendment 1124 #
Proposal for a regulation
Annex 1 – Part 2 – point 1 – point 1.4 – point 1.4.2 – paragraph 1
Annex 1 – Part 2 – point 1 – point 1.4 – point 1.4.2 – paragraph 1
Powered by the expansion of the knowledge of living systems, biotechnology is set to deliver a stream of new applications and to strengthen the Union's industrial base and its innovation capacity. Examples of the rising importance of biotechnology are in industrial applications including bio- chemicals, of which the market share is estimated to increase by up to 12 %-20 % of chemical production by 2015. A number of the so-called twelve rules of Green Chemistry are also addressed by biotechnology, due to the selectivity and efficiency of bio-systems. The possible economic burdens for Union enterprises can be reduced by harnessing the potential of biotechnology processes and bio-based products to reduce CO2 emissions, estimated to range from between 1 to 2.5 billion tons CO2 equivalent per year by 2030. In Europe's biopharmaceutical sector, already some 20 % of the current medicines are derived from biotechnology, with up to 50 % of new medicines. Biotechnology also opens new avenues for exploiting the huge potential of marine resources for producing innovative industrial, health, chemical, energy-related and environmental applications. The emerging sector of marine (blue) biotechnology has been predicted to grow by 10 % a year.
Amendment 1165 #
Proposal for a regulation
Annex 1 – Part 2 – point 1 – point 1.5 – point 1.5.3 – point c – paragraph 1
Annex 1 – Part 2 – point 1 – point 1.5 – point 1.5.3 – point c – paragraph 1
Increasing the competitiveness of process industries, by drastically improving resource and energy efficiencies and reducing the environmental impact of such industrial activities through the whole value chain, promoting the adoption of low-carbon technologies including the integration of renewable forms of energy and smart advanced monitoring systems.
Amendment 1261 #
Proposal for a regulation
Annex 1 – Part 2 – point 3 – point 3.3 – point d – paragraph 1
Annex 1 – Part 2 – point 3 – point 3.3 – point d – paragraph 1
Supporting market-driven innovation to improve the framework conditions for innovation and tackling the specific barriers preventing, in particular, the growth of innovative SMEs. Certain regulatory methodologies used to evaluate the ecotoxicity of substances impede the placing on the market of preparations made from complex natural substances. New methodologies need to be developed so that the environmental impact of complex natural substances can be evaluated more effectively.
Amendment 1267 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 2
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 2
Lifelong health and wellbeing for all, high- quality and economically sustainable health and care systems, solutions to deal with the autonomy of an ageing population and opportunities for new jobs and growth are the aims of support to research and innovation in response to this challenge and will make a major contribution to Europe 2020.
Amendment 1272 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 2 c (new)
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 2 c (new)
Research should allow to improve advanced therapies and cellular therapies that would be focused on the treatment of chronical and degenerative diseases.
Amendment 1275 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 3
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 3
The cost of Union health and social care systems is rising with care and prevention measures in all ages increasingly expensive, the number of Europeans aged over 65 expected to nearly double from 85 million in 2008 to 151 million by 2060, and those over 80 to rise from 22 to 61 million in the same period. Reducing or containing these costs such that they do not become unsustainable depends in part on ensuringinforming people better and encouraging responsible health choices so as to optimise the lifelong health and wellbeing of all and therefore on the effective prevention, treatment and management of disease and disability.
Amendment 1288 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 5
Annex 1 – Part 3 – point 1 – point 1.1 – paragraph 5
In the Union, CVD annually accounts for more than 2 million deaths and costs the economy more than EUR 192 billion while cancer accounts for a quarter of all deaths and is the number one cause of death in people aged 45-64. Over 27 million people in the Union suffer from diabetes and the total cost of brain disorders (including, but not limited to those affecting mental health) has been estimated at EUR 800 billion. Environmental, life-style and socio-economic factors are relevant in several of these conditions with up to one third of the global disease burden estimated to be related to these. However, for other conditions – in particular neurodegenerative diseases – effective prevention strategies will first require a considerable boost in research into their causes and the development of better early diagnosis and treatment options.
Amendment 1305 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.2 – paragraph 1
Annex 1 – Part 3 – point 1 – point 1.2 – paragraph 1
Disease and disability are not stopped by national borders. An appropriate European level research and innovation response in partnership with third countries can and should make a crucial contribution to addressing these global challenges, thereby working to achieve the Millennium Development Goals, deliver better health and wellbeing for all, and position Europe as a leader in the rapidly expanding global markets for health and wellbeing innovations.
Amendment 1316 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.2 – paragraph 2
Annex 1 – Part 3 – point 1 – point 1.2 – paragraph 2
The response depends on excellence in research to improve our fundamental understanding of health, disease, disability, development and ageing (including of life expectancy), and on the seamless and widespread translation of the resulting and existing knowledge into innovative, scalable and, effective and accessible products, strategies, interventions and services. Furthermore, the pertinence of these challenges across Europe and in many cases, globally, demands a response characterised by long term and coordinated support for co- operation between excellent, multidisciplinary and multi-sector teams.
Amendment 1326 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 2 a (new)
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 2 a (new)
Amendment 1334 #
Proposal for a regulation
Annex 1 – section 3 – point 1 – point 1.3 – paragraph 3
Annex 1 – section 3 – point 1 – point 1.3 – paragraph 3
An increasing disease and disability burden in the context of an aging population places further demands on health and care sectors. If effective health and care is to be maintained for all ages, efforts are required to improve decision making in prevention and treatment provision, to identify and support the dissemination of best practice in the health and care sectors, and to support integrated care and the wide uptake of technological, organisational and social innovations empowering in particular older persons, persons with chronic diseases as well as disabled persons to remain active and independent. Doing so will contribute to increasing, and lengthening the duration of their physical, social, and mental well- being.
Amendment 1337 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 4
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 4
All of these activities shall be undertaken in such a way as to provide support throughout the research and innovation cycle, strengthening the competitiveness of the European based industries and development of new market opportunities. In the field of research on the problem of skin allergies for example, patch testing is currently the only means available to dermatologists to examine patients for type VI allergies. New more reliable methods are needed to assess whether a patient is allergic to a substance and to help identify the causality of exposure to a substance and the adverse effect on the skin.
Amendment 1341 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 4
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 4
All of these activities shall be undertaken in such a way as to provide support throughout the research and innovation cycle, strengthening the competitiveness of the European based industries and development of new market opportunities. Emphasis will also be placed on engaging all health stakeholders – including patient and patient organisations– in order to develop a research and innovation agenda that actively involves citizens and reflects their needs and expectations.
Amendment 1350 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 5
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 5
«« Specific activities shall include: understanding the determinants of health (including environmental and climate related factors), improving health promotion and disease prevention; understanding disease and improving diagnosis in different socio-economic contexts; developing effective screening programmes and improving the assessment of disease susceptibility; improving the surveillance and preparednesof infectious diseases in the Union as well as in neighbouring and developing countries and preparedness for combating epidemics and emerging diseases; developing better preventive vaccines; using in-silico medicine for improving disease management and prediction; treating disease; transferring knowledge to clinical practice and scalable innovation actions; better use of health data; active ageing, independent and assisted living; individual empowerment for self-management of health; promotion of integrated care; improving scientific tools and methods to support policy making and regulatory needs; and optimising the efficiency and effectiveness of healthcare systems and reducing inequalities by evidence based decision making and dissemination of best practice, and innovative technologies and approaches.
Amendment 1352 #
Proposal for a regulation
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 5
Annex 1 – Part 3 – point 1 – point 1.3 – paragraph 5
Specific activities shall include: understanding the determinants of health (including environmental and climate related factors), improving health promotion and disease prevention; understanding disease and improving diagnosisthe mechanisms underlying disease and toxicity and improving diagnosis and understanding of biomarkers and modes of action; developing effective screening programmes and improving the assessment of disease susceptibility; improving surveillance and preparedness; developing better preventive vaccines; using in-silico medicine for improving disease management and prediction; treating disease; transferring knowledge to clinical practice and scalable innovation actions; better use of health data; active ageing, independent and assisted living; individual empowerment for self-management of health; promotion of integrated care; improving scientific tools and methods relevant to an understanding of health and human diseases to support policy making and regulatory needs; and optimising the efficiency and effectiveness of healthcare systems and reducing inequalities by evidence based decision making and dissemination of best practice, and innovative technologies and approaches.
Amendment 1457 #
Proposal for a regulation
Annex 1 – Part 3 – point 3 – point 3.1 – paragraph 4
Annex 1 – Part 3 – point 3 – point 3.1 – paragraph 4
To achieve these reductions, significant investments need to be made in research, development, demonstration and market roll-out of efficient, safe and reliable low- carbon energy technologies and services. These must go hand in hand with non- technological solutions on both the supply and demand sides. All this must be part of an integrated low-carbon policy, including mastering key enabling technologies, in particular ICT solutions and advanced manufacturing, processing and materials. The goal is to produce efficient energy technologies and services that can help take up the energy challenges relating in particular to the integration of renewable energies and can be taken up widely on European and international markets and to establish intelligent demand-side management based on an open and transparent energy trade market and intelligent energy efficiency management systems.
Amendment 1483 #
Proposal for a regulation
Annex 1 – Part 3 – point 3 – point 3.2 – paragraph 8
Annex 1 – Part 3 – point 3 – point 3.2 – paragraph 8
Research and innovation activities on nuclear fission and fusion energy are carried out in the EURATOM part of Horizon 20200, but there must be coordination with action on energy challenges in order to foster synergies between the two programmes and establish a comprehensive and coherent roadmap for European R&D in the area of energy.
Amendment 1490 #
Proposal for a regulation
Annex 1 – Part 3 – point 3 – point 3.3 – point a – paragraph 1
Annex 1 – Part 3 – point 3 – point 3.3 – point a – paragraph 1
Activities shall focus on research and full- scale testing of new concepts, non- technological solutions, more efficient, socially acceptable and affordable technology components and systems with in-built intelligence, to allow real-time energy management for cities and territories, near-zero-emission buildings, renovated buildings, renewable heating and cooling (including energy produced through waste recovery), highly efficient industries and mass take-up of energy efficiency solutions by companies, individuals, communities and cities.
Amendment 1513 #
Proposal for a regulation
Annex 1 – Part 3 – point 3 – point 3.3 – point d – introductory part
Annex 1 – Part 3 – point 3 – point 3.3 – point d – introductory part
(d) A single, flexible, reliable and smart European electricitnergy grid
Amendment 1522 #
Proposal for a regulation
Annex 1 – Part 3 – point 3 – point 3.3 – point d – paragraph 1
Annex 1 – Part 3 – point 3 – point 3.3 – point d – paragraph 1
Activities shall focus on research, development and full scale demonstration of new grid technologies, including storage, systems and market designs to plan, monitor, control and safely operate interoperable and flexible networks in an open, decarbonised, climate resilient and competitive market, under normal and emergency conditions.
Amendment 1527 #
Proposal for a regulation
Annex 1 – Part 3 – point 3 – point 3.3 – point e – paragraph 1
Annex 1 – Part 3 – point 3 – point 3.3 – point e – paragraph 1
Activities shall focus on multi-disciplinary research for energy technologies for exploration, production, transmission and utilisation (including visionary actions such as CO2 recovery) and joint implementation of pan-European research programmes and world-class facilities.
Amendment 1529 #
Proposal for a regulation
Annex 1 – Part 3 – point 3 – point 3.3 – point f – paragraph 1
Annex 1 – Part 3 – point 3 – point 3.3 – point f – paragraph 1
Activities shall focus on the development of tools, methods and models and forward- looking scenarios for a robust and transparent policy support, including activities on public acceptance and engagement, user involvement, environmental impact assessment and sustainability.